Argent BioPharma Secures AU$11 Million Financing Facility for Strategic Acquisition

Argent BioPharma Ltd (ASX: RGT) has secured a new AU$11 million financing facility from US-based funds managed by C/M Capital Partners to complete the AusCann Group asset acquisition and support future commercial expansion. An initial AU$3 million drawdown will fund working capital and finalise the AusCann transaction, which includes the Neuvis drug-delivery platform, FDA-facing epilepsy pre-clinical data, access to a EU-GMP manufacturing facility, and a large German pharmaceutical distribution network.

The financing strengthens Argent’s 2026 operating runway while supporting growth of its cannabinoid-based medicines CannEpil® and CimetrA® across North and South America. Board changes accompany the transaction, including Andrew Chapman joining as Executive Director and Roby Zomer transitioning to Non-Executive Chairman.

Argent also executed a deed of variation updating conversion pricing and maturity terms for existing convertible notes, streamlining its capital structure as it advances toward a planned dual US stock-exchange listing.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com